SUZANNE GAZDA M.D.
  • Home
  • Meet Dr. Gazda
    • Our Practice
  • Lectures/Videos
  • BLOGS
    • Blog - Long Covid
    • Blog - NEUROLOGY TRENDS
    • Blog - MS in the NEWS
    • Blog - Scientifically Speaking
    • Blog - Guest Articles
  • Our Approach
  • Conditions we treat
    • Alzheimer’s Disease
    • Amyotrophic Lateral Sclerosis (ALS)
    • Long COVID
    • Multiple Sclerosis (MS)
    • PANS | PANDAS
    • Parkinson’s disease
  • Treatment Protocols
  • Patient Stories
  • FAQ
  • Policies & Rates
  • Helpful LInks
  • Medical Resources
  • Journal Articles
  • Product Recommendations
  • Become a Patient
  • NEWS
  • Contact

Scientifically Speaking

Alpha-synuclein in neurodegenerative disease.

10/7/2020

0 Comments

 
Picture
The SNCA gene provides instructions for making a small protein called alpha-synuclein. Alpha-synuclein is abundant in the brain, and smaller amounts are found in the heart, muscles, and other tissues. In the brain, alpha-synuclein is found mainly at the tips of nerve cells (neurons) in specialized structures called presynaptic terminals. Presynaptic terminals release chemical messengers, called neurotransmitters, from compartments known as synaptic vesicles. The release of neurotransmitters relays signals between neurons and is critical for normal brain function.
Although the function of alpha-synuclein is not well understood, studies suggest that it plays an important role in maintaining an adequate supply of synaptic vesicles in presynaptic terminals. It may also help regulate the release of dopamine, a neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements. Alpha-synuclein may also play a role in the movement of structures called microtubules that help cells maintain their shape.1
 
We know that genes are one part of the story, but the even more telling piece is epigenetics. Environmental factors influence gene expression so it is one thing to “carry the gene,” but the most important points we have to consider are the environmental risk factors that help trigger or turn on the genes we carry through life.   
 
What recently has especially come to light is that once started, these neurodegenerative diseases may propagate themselves; misfolding leads to a domino effect as more and more proteins become misfolded and are incorporated into a large, ever-growing abnormal clump of material in the brain. This process is similar to what we know has happened before with prion diseases (e.g. mad cow disease, Kuru, combined immunodeficiency disease), which are considered very rare. However, in recent years, scientists have discovered that similar processes of protein misfolding are at work in many neurodegenerative disorders including Alzheimer’s, Parkinson’s and Lou Gehrig’s disease. Prion refers to abnormal, pathogenic agents that are transmissible and are able to induce abnormal folding of specific normal cellular proteins called prion proteins that are found most abundantly in the brain.2  Research has shown as well beyond a shadow of doubt that Alzheimer’s is a prion disease where the amyloid and tau can also “self-propagate.”3
 
In integrative medicine, we must look to all factors of disease initiation to best understand its likely progression in order to identify the most appropriate treatment protocols. Alpha-synuclein is clearly a factor in neurodegenerative disorders and the more we can learn about its actions will hopefully provide us with the insight to diagnose more patients at an earlier stage.
 
1 U.S. Library of Medicine – The SNCA gene
https://ghr.nlm.nih.gov/gene/SNCA
 
2 Centers for Disease Control and Prevention – Prion diseases
https://www.cdc.gov/prions/index.html
 
3 University of California San Francisco – Alzheimer’s disease and prions
https://www.ucsf.edu/news/2019/05/414326/alzheimers-disease-double-prion-disorder-study-show
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Author

    by Suzanne Gazda M.D.
    Here you’ll find a collection of articles and information from a more-scientific perspective about many aspects of the neurological conditions we treat at Gazda Integrative Neurology.
    Please check back often as new items are regularly added.

    Archives

    August 2021
    February 2021
    January 2021
    November 2020
    October 2020
    August 2020
    July 2020
    May 2020
    April 2020
    January 2020
    November 2019
    October 2019

    Categories

    All

    RSS Feed

SITE MAP

HOME
MEET DR. GAZDA
OUR PRACTICE
INTEGRATIVE MEDICINE
OUR APPROACH
CONDITIONS WE TREAT
TREATMENT PROTOCOLS
PATIENT STORIES
FAQ
POLICIES & RATES
BLOG
SCIENTIFICALLY SPEAKING
MEDICAL RESOURCES
JOURNAL ARTICLES
LINKS
BECOME A PATIENT
CONTACT
NEWS
PRODUCT RECOMMENDATIONS

Location

San Antonio, Texas

Telephone

210-692-1245
Fax
210-692-9311

Email

[email protected]
  • Home
  • Meet Dr. Gazda
    • Our Practice
  • Lectures/Videos
  • BLOGS
    • Blog - Long Covid
    • Blog - NEUROLOGY TRENDS
    • Blog - MS in the NEWS
    • Blog - Scientifically Speaking
    • Blog - Guest Articles
  • Our Approach
  • Conditions we treat
    • Alzheimer’s Disease
    • Amyotrophic Lateral Sclerosis (ALS)
    • Long COVID
    • Multiple Sclerosis (MS)
    • PANS | PANDAS
    • Parkinson’s disease
  • Treatment Protocols
  • Patient Stories
  • FAQ
  • Policies & Rates
  • Helpful LInks
  • Medical Resources
  • Journal Articles
  • Product Recommendations
  • Become a Patient
  • NEWS
  • Contact